GH Research (GHRS) Projected to Post Earnings on Thursday

GH Research (NASDAQ:GHRS) is expected to release its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect GH Research to post earnings of ($0.27) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 14, 2026 at 12:30 PM ET.

GH Research (NASDAQ:GHRS) last released its quarterly earnings data on Friday, March 6th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.06. On average, analysts expect GH Research to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

GH Research Trading Up 4.7%

GH Research stock opened at $21.69 on Tuesday. GH Research has a 1-year low of $9.46 and a 1-year high of $24.66. The firm has a market capitalization of $1.35 billion, a price-to-earnings ratio of -27.11 and a beta of 1.27. The firm’s fifty day moving average price is $16.05 and its two-hundred day moving average price is $15.03.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on GHRS. Canaccord Genuity Group raised their price objective on shares of GH Research from $35.00 to $39.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Guggenheim set a $34.00 price target on shares of GH Research and gave the company a “buy” rating in a research report on Tuesday, March 10th. Royal Bank Of Canada raised their price target on shares of GH Research from $33.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, January 23rd. Citigroup reissued a “market outperform” rating on shares of GH Research in a research report on Tuesday, January 6th. Finally, Needham & Company LLC raised their price target on shares of GH Research from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, March 6th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $40.13.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in GHRS. Barclays PLC lifted its position in shares of GH Research by 63.4% during the fourth quarter. Barclays PLC now owns 2,118 shares of the company’s stock valued at $27,000 after purchasing an additional 822 shares in the last quarter. Osaic Holdings Inc. raised its position in GH Research by 63.6% in the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after acquiring an additional 2,400 shares during the period. JPMorgan Chase & Co. bought a new stake in GH Research in the second quarter worth about $79,000. HRT Financial LP bought a new stake in GH Research in the fourth quarter worth about $202,000. Finally, BNP Paribas Financial Markets raised its position in GH Research by 165.4% in the second quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock worth $207,000 after acquiring an additional 10,600 shares during the period. 56.90% of the stock is owned by institutional investors.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.